NCT06835725View on ClinicalTrials.gov

Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

April 30, 2032

Study Completion Date

April 30, 2033

Conditions
Prostate CA
Interventions
RADIATION

Stereotactic Body Radiation Therapy (SBRT)

prostate stereotactic ablative radiotherapy

Trial Locations (1)

V8R6V5

RECRUITING

BC Cancer Radiation Oncology, Victoria

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER

NCT06835725 - Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer | Biotech Hunter | Biotech Hunter